FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) Meeting Abstract
| Authors: | Moore, K.; Oza, A.; Colombo, N.; Oaknin, A.; Scambia, G.; Lorusso, D.; Farias-Eisner, R.; Banerjee, S.; Murphy, C.; Tanyi, J.; Hirte, H.; Konner, J.; Lim, P.; Prasad Hayes, M.; Monk, B.; Kim, S.; Wang, J.; Pautier, P.; Vergote, I.; Birrer, M. |
| Abstract Title: | FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz250 |
| Language: | English |
| ACCESSION: | WOS:000491295503041 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz250 |
| Notes: | Meeting Abstract: 992O -- Source: Wos |
